Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04014647

Measurement Of NT-proBNP to Predict Outcomes in Surgery

The team is investigating whether N-terminal pro B-type natriuretic peptide (NT-proBNP) and other cardiac markers are useful for predicting outcomes for patients undergoing vascular surgery. By measuring NT-proBNP before and after surgery, the investigators may be able to determine which patients are at risk of an adverse outcome, such as a heart attack or death.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

Almost 1 in 5 patients who have elective major vascular surgery experience death or a myocardial infarction (MI) at 18 months post-surgery. Research has shown that peri-operative interventions may improve outcomes for high-risk patients. Cardiac bio-markers may be used to identify these high-risk patients, in particular pre- and post-operative NT-proBNP.

Mahla found that by comparing surgery outcomes with NT-proBNP concentrations peri-operatively, high-risk patients could be identified and subsequent therapeutic decisions could be made to minimise adverse outcomes.

Van Kimmenade evaluated patients with acute heart failure and found that galectin-3 (Gal-3) was the best predictor of 60-day mortality compared with NT-proBNP and apelin (another cardiac marker), whereas NT-proBNP was the most useful for diagnosing HF. The authors also found that the combination of both markers (Gal-3 and NT-proBNP) have an even higher predictive value for outcome.

The predictive role of troponin I (cTnI) has been observed in a paper by Bursi et al. (2005) where patients undergoing elective major vascular surgery were stratified using the American College of Cardiology/American Heart Association (ACC/AHA) guidelines and followed up over a period of 24 months. Patients in every group with an elevated post-operative cTnI (≥100ng/L) were at greater risk of either MI or death.

The successful identification of high-risk patients can go on to have interventional risk-reducing pharmacological, therapeutic, diagnostic, or observational measures.

Prevention of cardiovascular events, particular for an aging population, can have positive impact on both the patient and society as a whole as it may result in patients maintaining their independence, avoiding major illness, avoiding nursing home care and living longer.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who are equal to or over 18 years old
  • Patients scheduled to undergo elective surgery for the following procedures:
  • Infrainguinal arterial reconstruction
  • Aortic aneurysm
  • Aorto-bifemoral bypass / or aortic endarterectomy
  • Femoro-popliteal bypass
  • Femoro-distal bypass
  • Femoral endarterectomy
  • Femoro-femoral crossover
  • Axillo-femoral bypass
  • Elective carotid surgery
  • Patients having either general or regional anaesthesia for their surgery

Exclusion criteria

-

  • Patients undergoing emergency surgery
  • Those who are unable or unwilling to give informed consent
  • Patients with unstable coronary syndromes (acute or recent MI with evidence of important ischemic risk by clinical symptoms or stress testing or unstable or severe angina pectoris)
  • Patients with decompensated heart failure (new onset shortness of breath and rales together with echocardiographic evidence of cardiac dysfunction or deterioration of chronic heart failure despite heart failure therapy)
  • Patients with chronic atrial fibrillation

Treatment and study plan

Primary outcomes

  1. NT-proBNP blood test measured on the day of (pre-) vascular surgery

    Time frame: 4 days

    NT-proBNP blood test measured on the day of (pre-) vascular surgery

  2. NT-proBNP blood test measured on the day 4 after (post-) vascular surgery

    Time frame: 4 days

    NT-proBNP blood test measured on the day 4 after (post-) vascular surgery

  3. Change in NT-proBNP peri-operatively

    Time frame: 4 days

    Change in NT-proBNP peri-operatively

Secondary outcomes

  1. Pre-, post-, and peri-operative troponin I

    Time frame: 4 days

    Pre-, post-, and peri-operative troponin I

  2. Pre-, post-, and peri-operative galectin-3

    Time frame: 4 days

    Pre-, post-, and peri-operative galectin-3

  3. Pre-, post-, and peri-operative CRP

    Time frame: 4 days

    Pre-, post-, and peri-operative CRP

  4. Pre-, post-, and peri-operative creatinine

    Time frame: 4 days

    Pre-, post-, and peri-operative creatinine

Study contacts

Contact information is provided by the study sponsor or research team.

Allison Chipchase, Dr

CONTACT

[email protected]

+44(0)1603-286-929

Emma Miler, MSc BSc Hons

CONTACT

[email protected]

+44(0)1603-286-932

Sponsors and collaborators

Lead sponsor

Norfolk and Norwich University Hospitals NHS Foundation Trust

Other

Registry information

Official study title

Peri-operative Measurement of NT-proBNP to Predict Outcomes in Patients Undergoing Elective Vascular Surgery

Acronym: MOBOS

Important dates

Study start
2019
Primary completion
2029
Study completion
2029
First posted
Jul 10, 2019
Registry last updated
Jun 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.